Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Terms & Conditions

EHA Meetings

Look back at EHA2024

Program by day

Program

Saturday, June 15, 2024 - Presidential Session I

Conducting multinational RCTs in pregnancy to improve maternal health in thrombosis: it CAN be done   

Prof.  Saskia Middeldorp, The Netherlands

Targeting the epigenome in lymphoma 

Prof.

Abstracts & awards

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).